Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Simulations Plus (Nasdaq: SLP), a leading provider of biosimulation and medical communications solutions for the biopharma industry, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 6, 2024, at the Marriott Marquis in New York.
CEO Shawn O'Connor will represent the company, hosting one-on-one and small group meetings throughout the day. This prestigious conference is expected to feature over 200 companies and attract a prominent group of investors, including chief investment officers, portfolio managers, and analysts.
The conference provides an excellent opportunity for Simulations Plus to showcase its innovative solutions and network with key industry players and investors. For those interested in learning more about the event, additional information can be found on the Morgan Stanley conference website.
Simulations Plus (Nasdaq: SLP), un fornitore leader di soluzioni di biosimulazione e comunicazione medica per l'industria biopharma, ha annunciato la sua partecipazione alla 22ª Conferenza Globale sulla Salute Annuale di Morgan Stanley. L'evento si terrà il 6 settembre 2024, presso il Marriott Marquis a New York.
Il CEO Shawn O'Connor rappresenterà l'azienda, ospitando incontri individuali e riunioni di piccoli gruppi durante la giornata. Questa prestigiosa conferenza prevede la partecipazione di oltre 200 aziende e attirerà un gruppo di investitori di spicco, tra cui chief investment officers, gestori di portafoglio e analisti.
La conferenza offre un'ottima opportunità per Simulations Plus per mostrare le sue soluzioni innovative e fare networking con i principali attori del settore e investitori. Per coloro che sono interessati a saperne di più sull'evento, ulteriori informazioni possono essere trovate sul sito web della conferenza di Morgan Stanley.
Simulations Plus (Nasdaq: SLP), un proveedor líder de soluciones de biosimulación y comunicación médica para la industria biofarmacéutica, ha anunciado su participación en la 22ª Conferencia Global Anual sobre Salud de Morgan Stanley. El evento se llevará a cabo el 6 de septiembre de 2024 en el Marriott Marquis de Nueva York.
El CEO Shawn O'Connor representará a la empresa, organizando reuniones uno a uno y reuniones para grupos pequeños durante todo el día. Se espera que esta prestigiosa conferencia cuente con más de 200 empresas y atraiga a un grupo destacado de inversores, incluyendo directores de inversiones, gerentes de cartera y analistas.
La conferencia ofrece una excelente oportunidad para Simulations Plus de exhibir sus soluciones innovadoras y establecer contactos con actores clave de la industria e inversores. Para aquellos interesados en obtener más información sobre el evento, se pueden encontrar más detalles en el sitio web de la conferencia de Morgan Stanley.
Simulations Plus (Nasdaq: SLP)는 생명공학 및 제약 산업을 위한 생물 시뮬레이션 및 의료 커뮤니케이션 솔루션의 선도적인 공급업체로서 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 6일 뉴욕의 매리어트 마퀴스에서 개최됩니다.
CEO Shawn O'Connor는 회사를 대표하며 하루 종일 일대일 및 소규모 그룹 회의를 주최합니다. 이 권위 있는 컨퍼런스는 200개 이상의 기업가 참여할 것으로 예상되며, 투자 책임자, 포트폴리오 매니저 및 분석가를 포함한 저명한 투자자들이 모일 것입니다.
이번 컨퍼런스는 Simulations Plus가 혁신적인 솔루션을 선보이고 산업 주요 인사 및 투자자들과 네트워크를 형성할 수 있는 훌륭한 기회를 제공합니다. 행사에 대한 추가 정보는 모건 스탠리 컨퍼런스 웹사이트에서 확인하실 수 있습니다.
Simulations Plus (Nasdaq: SLP), un fournisseur de premier plan de solutions de biosimulation et de communication médicale pour l'industrie biopharmaceutique, a annoncé sa participation à la 22e Conférence mondiale annuelle sur la santé de Morgan Stanley. L'événement se tiendra le 6 septembre 2024 au Marriott Marquis à New York.
Le PDG Shawn O'Connor représentera l'entreprise en animant des réunions one-on-one et des petites réunions tout au long de la journée. Cette conférence prestigieuse devrait réunir plus de 200 entreprises et attirer un groupe d'investisseurs de renom, incluant des directeurs d'investissement, des gestionnaires de portefeuille et des analystes.
La conférence offre une excellente occasion pour Simulations Plus de mettre en avant ses solutions innovantes et de nouer des contacts avec des acteurs clés de l'industrie et des investisseurs. Pour ceux qui souhaitent en savoir plus sur l'événement, des informations supplémentaires peuvent être trouvées sur le site Web de la conférence de Morgan Stanley.
Simulations Plus (Nasdaq: SLP), ein führender Anbieter von Biosimulations- und medizinischen Kommunikationslösungen für die Biopharma-Industrie, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt gegeben. Die Veranstaltung findet am 6. September 2024 im Marriott Marquis in New York statt.
CEO Shawn O'Connor wird das Unternehmen vertreten und ganztägig Einzelgespräche sowie Meetings in kleinen Gruppen abhalten. Es wird erwartet, dass diese renommierte Konferenz mehr als 200 Unternehmen umfasst und eine prominente Gruppe von Investoren anzieht, darunter Chief Investment Officers, Portfoliomanager und Analysten.
Die Konferenz bietet Simulations Plus eine hervorragende Gelegenheit, seine innovativen Lösungen vorzustellen und mit wichtigen Akteuren der Branche sowie Investoren zu netzwerken. Weitere Informationen über die Veranstaltung sind auf der Website der Morgan Stanley-Konferenz erhältlich.
- None.
- None.
This event is expected to include more than 200 companies as well as a preeminent group of investor attendees, including chief investment officers, portfolio managers and analysts. For more information about the conference, please visit the Morgan Stanley conference website.
About Simulations Plus
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the Biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828878863/en/
Investor Relations Contacts:
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com
Renee Bouche
Simulations Plus Investor Relations
661-723-7723
renee.bouche@simulations-plus.com
Source: Simulations Plus, Inc.
FAQ
When and where is Simulations Plus (SLP) participating in the Morgan Stanley Healthcare Conference?
Who will represent Simulations Plus (SLP) at the Morgan Stanley Healthcare Conference?
What type of meetings will Simulations Plus (SLP) host at the Morgan Stanley conference?
How many companies are expected to participate in the Morgan Stanley Healthcare Conference with Simulations Plus (SLP)?
What types of investors are expected to attend the Morgan Stanley conference where Simulations Plus (SLP) is participating?
